Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy currently in clinical trials for PMM2-CDG, a rare genetic disease caused by glycosylation defects. This therapy aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
PMM2-CDG (also known as CDG-1A or CDG Type 1a) is a rare genetic disease of glycosylation caused by genetic mutations that lead to protein dysfunction and disruption of biochemical pathways. Currently approved therapies only treat symptoms and are not disease-modifying. This leaves a significant unmet need for treatments that address the underlying cause of the disease.
Solution
Glycomine is developing replacement therapies for rare genetic diseases, focusing on restoring missing biochemical functions to deliver meaningful improvements in quality of life for patients, caregivers, and families. Their lead drug, GLM101, is a mannose-1-phosphate replacement therapy currently in clinical trials in the U.S. and Europe for the treatment of PMM2-CDG. GLM101 aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.
Target Audience
The primary target audience includes patients diagnosed with PMM2-CDG, their caregivers, and their families.
Features
- GLM101: Mannose-1-phosphate replacement therapy
- Targets the underlying cause of PMM2-CDG by restoring the missing biochemical function
- Currently in Phase 2 clinical trials in the U.S. and Europe
- Designed to be disease-modifying, unlike existing symptomatic treatments